Factors associated with complete clinical response after neoadjuvant therapy in locally advanced rectal cancer: A Mexican retrospective study

Table 2 Patients achieving complete response after neoadjuvant (n = 20)

Variable	Value
Age (years)	61.6 ± 12.9
Sex
Male	12 (60.0)
Female	8 (40.0)
ECOG performance status
0	11 (55.0)
1	8 (40.0)
≥ 2	1 (5.0)
Distance from anal verge (cm)	5.0 (1.5-6.3)
Tumor length (cm)	5.8 ± 2.4
Baseline CEA (ng/mL)	3.2 (1.8-6.4)
Post-neoadjuvant CEA (ng/mL)	1.9 ± 0.8
Clinical T stage
≥ T3	17 (85.0)
≤ T2	3 (15.0)
Clinical N stage
Positive	14 (70.0)
Negative	6 (30.0)
Radiotherapy type
Long-course radiotherapy	18 (90.0)
Short-course radiotherapy	2 (10.0)
Neoadjuvant chemotherapy regimen
CAPOX	14 (70.0)
Capecitabine	3 (15.0)
FOLFOX	3 (15.0)
cCR	15 (75.0)
pCR	5 (25.0)
Local recurrence during follow-up among complete responders	(n = 20)
Yes	2 (10.0)
No	18 (90.0)

Data were showed as mean ± SD, median (interquartile range), or n (%). Both local recurrence events occurred exclusively in the complete clinical response watch-and-wait subgroup (2/15; 13.3%). ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic antigen; cCR: Complete clinical response; pCR: Pathological complete response.